Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
QED Therapeutics begins patient dosing in ph3 and ph 2 trials of Infigratinib
Details : The PROOF 302 trial is studying infigratinib for adjuvant treatment of invasive urothelial carcinoma. Second, investigator-initiated trial, is studying infigratinib for the treatment of solid tumors.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data will be presented reports consistent treatment response in both first-line and later-line treatment settings after Infigratinib (BGJ398) treatment in advanced/unresectable or metastatic urothelial carcinoma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2020
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable